Compare UVE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | CTMX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 977.1M |
| IPO Year | 1996 | 2015 |
| Metric | UVE | CTMX |
|---|---|---|
| Price | $36.91 | $3.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $40.00 | $12.10 |
| AVG Volume (30 Days) | 156.4K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $1,603,915,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $7.61 |
| P/E Ratio | ★ $20.02 | $22.58 |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $21.96 | $1.72 |
| 52 Week High | $41.96 | $8.21 |
| Indicator | UVE | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 36.09 |
| Support Level | $32.51 | $3.40 |
| Resistance Level | $41.32 | $3.91 |
| Average True Range (ATR) | 1.16 | 0.18 |
| MACD | -0.45 | 0.01 |
| Stochastic Oscillator | 1.98 | 21.58 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.